CALT News and Press, Calliditas Therapeutics AB From 06/29/22

Calliditas Therapeutics (NASDAQ:CALT) filed with the SEC for an at-the market-program to sell up to $75M American depositary shares (ADSs) at market price from time to time. The number of ADSs to be sold under the open market sale agreement with Jefferies will depend upon the number...

Calliditas Therapeutics establishes a U.S. At-the-Market Program PR Newswire STOCKHOLM, Sweden , June 28, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas" or "the Company") today an...

FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“ Celularity ”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board o...

A committee of the European Medicines Agency (EMA) recommended the conditional marketing authorization for Calliditas Therapeutics' (NASDAQ:CALT) Kinpeygo to treat symptoms of primary immunoglobulin A nephropathy (IgAN). IgAN is a type of kidney disease which occurs when an antibody...

Calliditas receives positive CHMP opinion in IgA nephropathy PR Newswire STOCKHOLM , May 19, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Committee for Medicinal Products...

Calliditas Therapeutics press release (NASDAQ:CALT): Q1 GAAP EPS of -SEK 3.95. Revenue of SEK 49.7M. Cash amounted to SEK 825.4M and SEK 867.3M as of March 31, 2022 and 2021, respectively. For further details see: Calliditas Therapeutics GAAP EPS of -SEK 3.95, revenue of SEK 49.7M

Calliditas Therapeutics: Interim Report Q1, 2022 PR Newswire STOCKHOLM , May 18, 2022 /PRNewswire/ -- Start of TARPEYO™ Commercial Launch in the US "During the first quarter Calliditas launched its first commercial product, TARPEYO, in the ...

First patient randomized in Phase 2 trial in head and neck cancer PR Newswire STOCKHOLM , May 17, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been ran...

Calliditas Therapeutics (NASDAQ:CALT) announces the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease. IgANConnect.com provides individuals diagnosed with IgA nephropathy and caregivers the tool...

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chro...